register

Communication

Janssen leader awarded Best PR Professional in Asia-Pacific region

Health Industry Hub | May 26, 2021 |

The PRWeek Awards Asia celebrates the most outstanding, inspired and successful campaigns, individuals and companies in the Asia-Pacific’s communications industry.

The 2021 winner of Best PR Professional in Asia-Pacific is Jenny Tear, Vice President of Communication & Public Affairs, Asia Pacific at Janssen, The Pharmaceutical Companies of Johnson & Johnson.

According to PRWeek, Jenny’s communications leadership is underpinned by a commitment to lead ‘from Asia, for Asia’. A champion both of local Asia Pacific talent on the global stage, in 2020 she successfully led a 32-strong team to enhance Janssen’s regional corporate reputation and support business growth.

In the face of significant internal and external challenges and uncertainty posed by Covid-19, Jenny delivered timely and empathetic communication to staff, hosted virtual events and wellbeing programmes. She also ran media training for Janssen’s regional leaders in support of Covid-19 vaccine messages, and secured tier one media interviews across all Asia Pacific markets.

Jenny achieved a 91% favourability rating in the year’s global employee survey from her team.

Appointed to her current position in 2010, Jenny has worked collaboratively with Asia Pacific leaders and regional and country communications teams to bolster communication, public affairs and corporate reputation capabilities in support of Janssen’s regional growth objectives.

According to PRWeek “Other external communication highlights included a youth-focused campaign around tuberculosis in collaboration with MTV Staying Alive Foundation, after which the Indian Government purchases 61,000 courses of a Janssen medicine; a collaboration between patient organisations and the fashion industry to develop clothing for people with psoriasis and reduce stigma around the condition; and a patient voice and medical opinion-led campaign which ultimately led to a record number of Janssen medicines being included on China’s National Reimbursement Drug List.”

Before joining Janssen, Jenny held senior in-house and public affairs consulting positions with organisations in Australia and the UK including Eli Lilly, Goodman Fielder, Gavin Anderson & Co, Department of Health and Ageing (Australia), Burson-Marsteller and Fleishman-Hillard.

While working in the Australian capital, Jenny managed major health policy change campaigns and advised the Department of Health and Pharmaceutical Benefits Advisory Committee.


News & Trends - Biotechnology

Aussie biotech secures agreement with UQ and USyd to advance cardiovascular diseases research

Aussie biotech secures agreement with UQ and USyd to advance cardiovascular diseases research

Health Industry Hub | July 26, 2024 |

Biotech News: Australian biotechnology company, Cartherics, developing immune cell therapies for the treatment of cancer, has entered into a Technology […]

More


News & Trends - MedTech & Diagnostics

NSW Health Secretary urges more focus on patient experience, drawing from her own heart valve disease journey

NSW Health Secretary urges more focus on patient experience, drawing from her own heart valve disease journey

Health Industry Hub | July 26, 2024 |

In a heart-warming event that united patients, their loved ones, representatives from patient organisations and employees, Edwards Lifesciences hosted its […]

More


Human Resources

'To be an inclusive society, we need an embedded national strategy to combat systemic racism', says Commissioner Sivaraman

‘To be an inclusive society, we need an embedded national strategy to combat systemic racism’, says Commissioner Sivaraman

Health Industry Hub | July 26, 2024 |

Race Discrimination Commissioner Giridharan Sivaraman has welcomed the release of the Multicultural Framework Review by the Federal Government, calling it […]

More


News & Trends - Pharmaceuticals

New shingles vaccine is linked with lower risk of dementia

Shingles vaccine lowers risk of dementia

Health Industry Hub | July 26, 2024 |

Pharma News: A recombinant shingles vaccine which was added to Australia’s National Immunisation Program (NIP) in November last year, is […]

More


This content is copyright protected. Please subscribe to gain access.